Introduction: Anti-vascular endothelial growth factor (VEGF) agents are the first-line therapies for macular edema, diabetic macular edema, and exudative age-related macular degeneration secondary to retinal vein occlusion. The gene discussed is VEGFA; the disease is retinal vein occlusion.